NCT05908409View on ClinicalTrials.gov

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 5, 2023

Primary Completion Date

December 22, 2025

Study Completion Date

March 22, 2026

Conditions
Multiple Myeloma (MM)Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDouble Hit LymphomaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedChronic Lymphocytic Leukemia (CLL)Triple Hit Lymphoma
Interventions
DRUG

IDP-121

IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models

Trial Locations (11)

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

30120

RECRUITING

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

37007

RECRUITING

Hospital Universitario de Salamanca, Salamanca

39008

RECRUITING

Hospital Universitario Marques de Valdecilla, Santander

08035

RECRUITING

Hospital Universitari Vall d'hebron, Barcelona

Unknown

RECRUITING

Hospital Durán i Reynals - ICO L´Hospitalet, Barcelona

RECRUITING

Hospital Universitario La Paz, Madrid

RECRUITING

Hospital Universitario Puerta de Hierro, Madrid

RECRUITING

Hospital Universitario Virgen del Rocio, Seville

RECRUITING

Hospital de Clinico Universitario de Valencia, Valencia

RECRUITING

Hospital Universitario Miguel Servet, Zaragoza

All Listed Sponsors
lead

IDP Discovery Pharma S.L.

INDUSTRY